Liminatus Pharma Inc surges amid market gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2025
0mins
Source: 8-K
Liminatus Pharma Inc's stock price increased by 61.02% in pre-market trading as it crossed above the 20-day SMA, reflecting strong investor interest.
The surge in Liminatus Pharma's stock is attributed to broad market strength, with the Nasdaq-100 up 0.54% and the S&P 500 up 0.26%, indicating a favorable environment for growth stocks.
This significant price movement may attract further attention from investors, potentially leading to increased trading volume and interest in the company's future developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LIMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LIMN
About LIMN
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Liminatus Pharma Receives Nasdaq Delisting Notice
- Delisting Notice: Liminatus Pharma received a delisting notice from Nasdaq on May 20, 2026, indicating the company has failed to regain compliance with Nasdaq's continued listing rules, which could lead to termination of its stock trading on Nasdaq.
- Compliance Issues: The company was previously notified of its non-compliance with Nasdaq's market value requirements of $50 million for listed securities and $15 million for publicly held shares, which directly impacts its credibility in the capital markets.
- Appeal Plans: Liminatus Pharma intends to appeal to the relevant panel in an effort to regain its listing status, a move that may influence investor confidence and the company's future financing capabilities.
- Financial Health Concerns: The delisting notice raises market concerns about Liminatus Pharma's financial health, potentially leading to stock price volatility and affecting its competitive position in the biopharmaceutical industry.
See More
Etsy Sells Depop to eBay for $1.2 Billion
- Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
- Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
- Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
- Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.
See More
U.S. Stocks Mostly Lower, Nasdaq Drops Over 50 Points
- Market Performance: U.S. stocks traded mostly lower on Tuesday, with the Nasdaq Composite falling over 50 points, and the S&P 500 dropping 0.13% to 6,827.16, indicating a cautious investor sentiment amid market weakness.
- Company Highlights: Medtronic PLC (NYSE:MDT) reported an adjusted EPS of $1.36 for Q3, exceeding market expectations of $1.33, with quarterly sales of $9.017 billion surpassing the $8.905 billion forecast, showcasing the company's strong earnings capability.
- Sector Dynamics: Financial shares gained 0.9%, while materials stocks fell by 2%, reflecting a divergence in market performance as investors may be seeking more defensive investment opportunities amidst volatility.
- Economic Indicators: According to ADP Research, U.S. private employers added an average of 10,250 jobs per week during the four weeks ending January 31, up from 7,750 in the previous period, indicating an improving labor market trend.
See More
U.S. Stocks Show Mixed Performance in Morning Trading
- Dow Jones Index Gains: On Tuesday, the Dow Jones index rose approximately 0.1%, trading up 0.06% to 49,529.45 points after the market opened, indicating a mild optimistic sentiment despite mixed overall performance.
- NASDAQ and S&P 500 Performance: The NASDAQ fell 0.03% to 22,540.83 points, while the S&P 500 gained 0.04% to 6,838.63 points, reflecting a divergence between tech stocks and blue-chip stocks, prompting investors to monitor sector dynamics closely.
- Manufacturing Index Decline: The NY Empire State Manufacturing Index dropped to 7.1 in February from 7.7 in January and below the market estimate of 7, indicating a slowdown in manufacturing activity that could impact overall economic growth expectations.
- Improved Employment Data: According to ADP Research, U.S. private employers added an average of 10,250 jobs per week during the four weeks ending January 31, compared to 7,750 in the prior period, suggesting a gradual recovery in the labor market.
See More
Credo Technology Raises Revenue Guidance Significantly
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
See More
Super Micro Computer Q2 Earnings Exceed Expectations
- Earnings Beat: Super Micro Computer reported Q2 earnings of $0.69 per share, surpassing the analyst consensus of $0.49 by 41.68%, indicating a significant improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $12.68 billion, exceeding the market estimate of $10.22 billion and representing a 123.76% increase from $5.68 billion in the same period last year, showcasing the company's strong market performance and growth potential.
- Optimistic Outlook: Super Micro expects Q3 adjusted EPS of $0.60, above the analyst estimate of $0.53, and anticipates revenue in the range of $12.3 billion to $12.6 billion, reflecting confidence in future performance.
- Positive Stock Reaction: In pre-market trading, Super Micro's shares jumped 10.5% to $32.79, indicating a favorable market response to its strong earnings and optimistic outlook.
See More
Liminatus Pharma Receives Nasdaq Delisting Notice
- Delisting Notice: Liminatus Pharma received a delisting notice from Nasdaq on May 20, 2026, indicating the company has failed to regain compliance with Nasdaq's continued listing rules, which could lead to termination of its stock trading on Nasdaq.
- Compliance Issues: The company was previously notified of its non-compliance with Nasdaq's market value requirements of $50 million for listed securities and $15 million for publicly held shares, which directly impacts its credibility in the capital markets.
- Appeal Plans: Liminatus Pharma intends to appeal to the relevant panel in an effort to regain its listing status, a move that may influence investor confidence and the company's future financing capabilities.
- Financial Health Concerns: The delisting notice raises market concerns about Liminatus Pharma's financial health, potentially leading to stock price volatility and affecting its competitive position in the biopharmaceutical industry.
See More
Etsy Sells Depop to eBay for $1.2 Billion
- Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
- Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
- Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
- Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.
See More
U.S. Stocks Mostly Lower, Nasdaq Drops Over 50 Points
- Market Performance: U.S. stocks traded mostly lower on Tuesday, with the Nasdaq Composite falling over 50 points, and the S&P 500 dropping 0.13% to 6,827.16, indicating a cautious investor sentiment amid market weakness.
- Company Highlights: Medtronic PLC (NYSE:MDT) reported an adjusted EPS of $1.36 for Q3, exceeding market expectations of $1.33, with quarterly sales of $9.017 billion surpassing the $8.905 billion forecast, showcasing the company's strong earnings capability.
- Sector Dynamics: Financial shares gained 0.9%, while materials stocks fell by 2%, reflecting a divergence in market performance as investors may be seeking more defensive investment opportunities amidst volatility.
- Economic Indicators: According to ADP Research, U.S. private employers added an average of 10,250 jobs per week during the four weeks ending January 31, up from 7,750 in the previous period, indicating an improving labor market trend.
See More
U.S. Stocks Show Mixed Performance in Morning Trading
- Dow Jones Index Gains: On Tuesday, the Dow Jones index rose approximately 0.1%, trading up 0.06% to 49,529.45 points after the market opened, indicating a mild optimistic sentiment despite mixed overall performance.
- NASDAQ and S&P 500 Performance: The NASDAQ fell 0.03% to 22,540.83 points, while the S&P 500 gained 0.04% to 6,838.63 points, reflecting a divergence between tech stocks and blue-chip stocks, prompting investors to monitor sector dynamics closely.
- Manufacturing Index Decline: The NY Empire State Manufacturing Index dropped to 7.1 in February from 7.7 in January and below the market estimate of 7, indicating a slowdown in manufacturing activity that could impact overall economic growth expectations.
- Improved Employment Data: According to ADP Research, U.S. private employers added an average of 10,250 jobs per week during the four weeks ending January 31, compared to 7,750 in the prior period, suggesting a gradual recovery in the labor market.
See More
Credo Technology Raises Revenue Guidance Significantly
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
See More
Super Micro Computer Q2 Earnings Exceed Expectations
- Earnings Beat: Super Micro Computer reported Q2 earnings of $0.69 per share, surpassing the analyst consensus of $0.49 by 41.68%, indicating a significant improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The quarterly revenue reached $12.68 billion, exceeding the market estimate of $10.22 billion and representing a 123.76% increase from $5.68 billion in the same period last year, showcasing the company's strong market performance and growth potential.
- Optimistic Outlook: Super Micro expects Q3 adjusted EPS of $0.60, above the analyst estimate of $0.53, and anticipates revenue in the range of $12.3 billion to $12.6 billion, reflecting confidence in future performance.
- Positive Stock Reaction: In pre-market trading, Super Micro's shares jumped 10.5% to $32.79, indicating a favorable market response to its strong earnings and optimistic outlook.
See More
